AngioSoma, Inc.
New website goes live in tandem with a major branding campaign to be found in USA Today.
RICHLAND, WA / ACCESSWIRE / July 21, 2021 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC) is launching its new website at www.globestarthera.com over the next 24 hours. Headquartered in Richland, Washington, GlobeStar Therapeutics Corporation is a fast-growing company focused on providing medical research, development and treatments for wellness and disease. With a mission to "help people begin their journeys to health," GlobeStar Therapeutics also brings high quality supplement products to the market.
"Now that our name change is complete it's time to unveil our new website which contains everything from corporate information to a health library," said James C. Katzaroff, President and CEO, GlobeStar Therapeutics Corporation. "This is simply the first step of many in our growth and expansion. GlobeStar Therapeutics is a company that understands the importance of continuing to strive to meet the challenges associated with Multiple Sclerosis and other neurodegenerative diseases."
The process to change the AngioSoma name to GlobeStar Therapeutics Corporation began many months ago and with the new name comes a robust information resource built on our history, drug path, and more. Within the health library you will find information on Multiple Sclerosis and other disease, blogs, and a full resource framework for anyone wants to learn more about these challenging neurodegenerative diseases.
GlobeStar Therapeutics Corporation.
GlobeStar Therapeutics Corporation (OTC PINK:GSTC) is a healthcare company dedicated to bringing innovative, effective and high-quality healthcare solutions to the medical community. With a focus on Multiple Sclerosis and other chronic diseases, GlobeStar's team is committed to helping those suffering begin their journey back to health. More information about GlobeStar Therapeutics Corporation can be found at www.globestarthera.com.
Notice Regarding Forward Looking Statements
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words "believes," "expects," "anticipate" or similar expressions. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Media Contact:
Brooke Greenwald
Cornerstone Communications, LTD
Brooke@cornerstonepr.net
240-360-0866
SOURCE: AngioSoma, Inc.
View source version on accesswire.com:
https://www.accesswire.com/656424/GlobeStar-Therapeutics-Corporation-Unveils-New-Corporate-Website-and-Branding-Campaign
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Global Sports Brand U.S. Polo Assn. Announced as Official Jersey and Apparel Sponsor for the Legendary Snow Polo World Cup St. Moritz13.1.2026 13:00:00 CET | Press release
WEST PALM BEACH, FL AND ST. MORITZ, SWITZERLAND / ACCESS Newswire / January 13, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), will make its debut as the Official Jersey and Apparel Sponsor of the 41stSnow Polo World Cup St. Moritz, taking place January 23-25, 2026, on the iconic frozen lake of St. Moritz. U.S. Polo Assn.'s inaugural partnership with the world's most prestigious and legendary snow polo tournament underscores the brand's authentic ties to the game and its continued commitment to supporting polo around the world.Photo Caption: Snow Polo World Cup St. Moritz, with Official Jersey and Apparel Sponsor, U.S. Polo Assn. Photo Credit: Christian Sommer Snow Polo World Cup St. Moritz 2026 is already shaping up to be a record-breaking year, with unprecedented demand for tickets, elite international players, and global attention focused on one of the world's most high-profile polo tournaments played on snow. This event will see more
Clean Air Metals Announces 2026 Strategic Objectives in Historically Strong PGE and Copper Markets13.1.2026 01:10:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / January 12, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU0(OTCQB:CLRMF) is pleased to provide an overview of its 2026 objectives and highlights of 2025, for its 100%-owned Thunder Bay North ("TBN") Critical Minerals Project in Northwestern Ontario. Critical Project Advancement Objectives Spot prices for platinum, copper and palladium have appreciated by 70% (1000 $/oz), 25% (1.20 $/lb) and 50% 624($/oz) respectively versus study prices, since the results of the Preliminary Economic Assessment (PEA) were announced in the October 9th release. Using the financial model published in the PEA and applying current spot metal prices (as of January 6th), the TBN project shows a $708M1 NPV8 and a pre-tax IRR of 100% (post-tax NPV8 = $494M1 and IRR = 84%).This is a significant improvement in the project outlook in comparison to the PEA results that featured a $219.4M2 pre-tax NPV8 and a pre-tax IRR of 39%. This year, cons
Germany Buys Eight MQ-9B SeaGuardian(R) RPA Through NSPA12.1.2026 20:00:00 CET | Press release
NSPA Supports NATO Countries in the Acquisition and Sustainment of GA-ASI's Advanced Multi-Domain RPA SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 12, 2026 / Germany's Federal Office of Bundeswehr Equipment, Information Technology and In-Service Support and the NATO Support and Procurement Agency (NSPA) have announced the procurement of eight MQ-9B SeaGuardian® Remotely Piloted Aircraft (RPA) from General Atomics Aeronautical Systems, Inc. (GA-ASI). The program includes four Certifiable Ground Control Stations. First delivery is expected in 2028. Germany joins a growing list of NATO countries that have selected GA-ASI's advanced MQ-9B RPA for its multi-domain capabilities with exceptionally long range and endurance. The platform provides pole-to-pole satellite control and de-icing capabilities to enable missions in cold climates. SeaGuardian features two multi-mode surface-search radars that deliver wide-area maritime surveillance, with an option to add Anti-Submarine Warfare capa
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom